ArticleDrug delivery2019
Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration.
Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Surfactant-Budesonide Combination to Prevent Death or Bronchopulmonary Dysplasia: A Systematic Review and Meta-Analysis.Neonatology · 2026Pooled it
- Comparative Efficacy and Safety Profile of the Combination of Pulmonary Surfactant and Budesonide vs. Surfactant Alone in the Management of Neonatal Respiratory Distress Syndrome: An Updated Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Efficacy and safety of intratracheal administration of budesonide combined with pulmonary surfactant in preventing bronchopulmonary dysplasia: a prospective randomized controlled trial.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Trial
- Multi-omics integration and machine learning identify a novel gene signature consisting of CCDC141, CHI3L2, RIMKLB, and PDLIM7 in bronchopulmonary dysplasia associated with neutrophil-driven immune dysregulation.Clinics (Sao Paulo, Brazil) · 2026Article
- Optimal postnatal corticosteroid regimens to prevent bronchopulmonary dysplasia with minimal adverse effects.Clinical and experimental pediatrics · 2026Article
- Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.Clinical reviews in allergy & immunology · 2025Review
- Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis.Archives of Iranian medicine · 2024Observational
- RETRACTED: Preparation and Analysis of Structured Color Janus Droplets Based on Microfluidic 3D Droplet Printing.Micromachines · 2023Article
- Preterm lung and brain responses to mechanical ventilation and corticosteroids.Journal of perinatology : official journal of the California Perinatal Association · 2023Review
- Influence of Physicochemical Properties of Budesonide Micro-Suspensions on Their Expected Lung Delivery Using a Vibrating Mesh Nebulizer.Pharmaceutics · 2023Article
- Beyond the Interface: Improved Pulmonary Surfactant-Assisted Drug Delivery through Surface-Associated Structures.Pharmaceutics · 2023Article
- New perpective for an old problem: extracellular vesicle based management of respiratory distress syndrome.Drug delivery · 2021Article
- Efficacy of intratracheal budesonide-surfactant combined therapy in surfactant-insufficient rat lungs with lipopolysaccharide insult.Journal of the Chinese Medical Association : JCMA · 2021Article
- Intra-tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants.Pediatric pulmonology · 2021Article
- Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging.Pharmaceutics · 2021Article
- Article
- Phenotypes of Bronchopulmonary Dysplasia.International journal of molecular sciences · 2020Review
- Microbiota and chronic lung disease in preterm infants. Where is the truth?Journal of perinatology : official journal of the California Perinatal Association · 2020Article
- Endotracheal Surfactant Combined With Budesonide for Neonatal ARDS.Frontiers in pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-tracheal instillation of budesonide using surfactant as a vehicle significantly decreased the incidence of bronchopulmonary dysplasia or death in preterm infants. The formularity of surfactant supplemented with budesonide and biophysical and chemical stability of the suspension has not been well reported. The aims are to investigate the biophysical and chemical stability of two surfactant preparations, Survanta and Curosurf, supplemented with budesonide. Biophysical property of the surface tension of Survanta and Survanta/budesonide suspension and of Curosurf and Curosurf/budesonide suspension was conducted by a pulsating bubble surfactometer and by a drop shape tensiometer. Chemical stability of Survanta/budesonide and of Curosurf/budesonide suspensions was tested by high-performance liquid chromatography analysis (HPLC). Pulmonary distribution of Survanta/
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.